The Best Non-Opioid Option, in the One Kidney That Can't Afford to Find Out
The trial evidence for opioid-sparing NSAID analgesia after ureteroscopy is genuinely strong. It just wasn't built with anyone in mind who has only one kidney to lose.
Ines D., a 45-year-old woman, works from a converted barn on her family's property forty-five minutes from the nearest hospital, translating technical manuals between Portuguese and English on a schedule flexible enough that she's rarely left the property for more than a day at a stretch in the three years since she moved back. She was born with a solitary functioning left kidney — the right never developed — a fact that has shaped every imaging study and every medication decision she's had since childhood, though it had never actually changed a treatment plan until now. A 9mm stone obstructing that one kidney required ureteroscopy yesterday, uncomplicated, with a stent left in place, and the question in front of the team this morning is how to manage her expected post-operative pain without leaning on opioids she'd rather avoid given the drive back to the barn.
The strongest recent evidence for opioid-sparing analgesia after ureteroscopy is the SKOPE trial, Fedrigon and colleagues' blinded noninferiority comparison of ketorolac against oxycodone in eighty-one patients. It is worth being precise about what it found, because it is routinely overstated: pain scores were no different, rescue-pill use was no different, and side effects were no different. What separated the groups was recovery — 1.3 days confined to bed on ketorolac against 2.3 on oxycodone. The case for the NSAID is that it matches the opioid and gets people up sooner, not that it measurably cut opioid consumption. It's exactly the kind of trial this decision would normally defer to. What it wasn't built to answer is what happens in a kidney that has no partner to compensate if COX inhibition blunts the prostaglandin-mediated vasodilation a stressed, recently-instrumented kidney depends on to maintain its own blood flow — a mechanistic concern that doesn't require a positive kidney biopsy to be real, only a kidney with zero functional reserve to fall back on if it materializes.
Morning rounds, post-op day one
SKOPE is the best evidence we have for exactly this question — Fedrigon's blinded noninferiority comparison of ketorolac against oxycodone after ureteroscopy — and ketorolac matched the opioid on pain while getting patients out of bed a full day sooner. It didn't cut rescue opioid use, to be fair to the data; it made the opioid unnecessary as a first-line choice. For a woman who lives forty-five minutes out and would rather not be sedated at that distance, that's the relevant finding.
I'd stop short of that here specifically. Prostaglandins mediate afferent arteriolar vasodilation — a real compensatory pathway a recently instrumented, transiently edematous kidney leans on to maintain its own blood flow. Blocking that with a COX inhibitor is a mechanistic concern that doesn't need a positive biopsy to be real.
Ines has no second kidney to compensate if that flow drops, even briefly. That's not a theoretical worry — it's the specific scenario a solitary kidney can't absorb the way a paired one can.
You're both reading the evidence correctly for what it actually says — the disagreement is really about whether it says anything about Ines at all.
SKOPE enrolled eighty-one unselected ureteroscopy patients, a group in which a solitary kidney is rare enough that the trial can't have carried more than a handful, and its own senior author's stated caveat on publication was that NSAIDs should generally be avoided in chronic kidney disease. Applying a noninferiority finding from that population to Ines isn't extending strong evidence — it's extending it past the boundary the investigators themselves drew.
Given that gap, I'd manage her postoperatively without an NSAID: scheduled acetaminophen plus a limited course of oxycodone for breakthrough pain, accepting that we're trading some analgesic efficacy for a margin of renal safety she genuinely can't spare.
Agreed: scheduled acetaminophen as the analgesic foundation, with a small quantity of oxycodone for breakthrough pain only, explicitly avoiding NSAIDs given her solitary-kidney anatomy. The group was direct with Ines that this trades some of the analgesic efficacy SKOPE demonstrated for a margin of renal safety her anatomy doesn't allow room to test.
Given her distance from the hospital, she was given clear return precautions (decreased urine output, new flank pain, fever) rather than a follow-up call as the primary safety net.